Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.26

+1.2%

Nov 11 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (6503)	6/7/2002 10:48:58 AM
From: rkrw	Read Replies (2) of 52153

George, I don't understand why you think all of biotech hinges on an fda amevive decision. btw: I still think xanelim, at best, will be an also ran in the psoriasis market. Speaking of biotech valuations, here's a list of bio's selling below cash on hand (a few have cv debt). acla alxn arna bcrx calp crgn cris cvas cvtx dcrn dovp emis gene genxy glfd gtcb (gztc) idev imgn incy inhl kdus lsbc lynx maxm pcyc prcs sepr vgnx vphm

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next